Figure 2.
Least square means of combined active lesions, gadolinium (Gd)-enhancing lesions, and T2 lesions over time adjusted by respective baseline at day 0. There was no significant treatment effect observed for new T2 active lesions (p = 0.1), new active Gd lesions (p = 0.29), or for combined active lesions (CAL) (p = 0.15).